A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

Conditions

• Atopic Dermatitis
• Eczema, Atopic

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• PF-08049820 — DRUG
  Tablet
• Placebo — DRUG
  Tablet

Study Details

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are aged 18 years or older; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.

Key Dates

Start date

Nov 20, 2025

Status verified

May 2026

Primary completion

Feb 2, 2028

Completion

Feb 2, 2028

Study Design

Enrollment

165 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm 1
  Stages 1 and 2: Tablets taken by mouth daily for 12 weeks
• Experimental: Arm 2
  Stages 1 and 2: Tablets taken by mouth daily for 12 weeks
• Experimental: Arm 3
  Stages 1 and 2: Tablets taken by mouth daily for 12 weeks
• Placebo Comparator: Arm 4
  Stages 1 and 2: Tablets taken by mouth daily for 12 weeks

Primary Outcome Measure

Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 12 [ Time Frame: Week 12 ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (4)

Find similar trials in Northridge, CA

Related Studies

• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
  PHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
• Molecular Signatures of Cutaneous Dupilumab Response
  PHASE4 · Recruiting · University of California, San Francisco · San Francisco, California
• Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
  Recruiting · University of California, San Diego · La Jolla, California
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
  PHASE2 · Recruiting · Pfizer · Birmingham, Alabama